Xspray Pharma publishing Interim Report Q2, January-June 2018
“The second quarter involved continued intensive work for Xspray, primarily in-house. We executed the planned additions to our organization through successful recruitment work. I’m really satisfied with the competences the company has succeeded in bringing in. We improved all core competences necessary for late-stage drug development including regulatory affairs, quality and process validation.” Per Andersson, CEO Xspray Pharma AB (publ)Second quarter, April-June 2018 Figures in brackets are for the corresponding period of the previous year. • Profit/loss before tax was SEK –6,789,